Piramal Pharma Q1 Results Review - Strong Orderbook, Cost Efficiencies Boosting A Turnaround: ICICI Securities

ICICI Securities Report

Piramal Pharma Ltd. Q1 FY25 result was driven by better traction in innovative contract development and manufacturing organization portfolio (50% of CDMO sales). Q1 is a seasonally weak quarter due to which its margins (10.5% in Q1 FY25 versus 20.8% in Q4 FY24) are volatile.

It will focus on CDMO business to improve utilisation of existing sites and add more molecules in pipeline. Complex health generics performance was tepid (up 2.3% YoY) in Q1; the company is adding capacities in India to drive cost efficiencies and boost growth.

Capex ($85-90 million in FY25) for new capacities may restrict its ability to generate free cashflow and repay debt in near future. Management maintains guidance of 14-15% growth in revenue and Ebitda in FY25; better order inflow of commercial innovative CDMO molecules may surprise positively.

Maintain 'Buy' raise target price to Rs 200.

Click on the attachment to read the full report:

DISCLAIMER

This report is authored by an external party. NDTV Profit does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of NDTV Profit.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.